Top Markets
#1 TENDIES TENDIES +59.72%
#2 Threshold Network Threshold Network +48.06%
#3 Cash Cat Cash Cat +25.61%
#4 Akedo Akedo +23.45%
#5 OSK OSK +16.28%
#6 Kinetiq Kinetiq +15.49%
#7 Maple Finance Maple Finance +14.59%
#8 Ape and Pepe Ape and Pepe +12.62%
#9 Falcon Finance Falcon Finance +12.36%
#10 Magma Finance Magma Finance +12.35%
Coin of the day
TENDIES TENDIES
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Neumora Therapeutics, Inc. Common Stock Neumora Therapeutics, Inc. Common Stock

Neumora Therapeutics, Inc. Common Stock

NMRA
Rang in Aktien #17292
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company... Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
Aktienkurs
$1.35
Zuletzt synchronisiert: 2026-09-01
Marktkapitalisierung
$249.21M
Veränderung (1 Tag)
1.13%
Veränderung (1 Jahr)
-22.70%
Land
US
Handel Neumora Therapeutics, Inc. Common Stock (NMRA)

Kategorie

Healthcare
Gewinn für Neumora Therapeutics, Inc. Common Stock (NMRA)
Gewinn im 2026 TTM: 0
Laut den aktuellen Finanzberichten von Neumora Therapeutics, Inc. Common Stock betragen die aktuellen Gewinne des Unternehmens 0. Im Jahr 2026 erzielte das Unternehmen einen Gewinn von 0, gleich wie dem Gewinn im Jahr 2026, der 0 betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Neumora Therapeutics, Inc. Common Stock von 2026 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
Nicht genügend Daten für die angegebenen Daten.
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH